42 related articles for article (PubMed ID: 38629654)
21. Road map for pain management in pancreatic cancer: A review.
Lahoud MJ; Kourie HR; Antoun J; El Osta L; Ghosn M
World J Gastrointest Oncol; 2016 Aug; 8(8):599-606. PubMed ID: 27574552
[TBL] [Abstract][Full Text] [Related]
22. Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration.
Ganai SA; Ramadoss M; Mahadevan V
Curr Neuropharmacol; 2016; 14(1):55-71. PubMed ID: 26487502
[TBL] [Abstract][Full Text] [Related]
23. HDAC and HAT inhibitors differently affect analgesia mediated by group II metabotropic glutamate receptors.
Zammataro M; Sortino MA; Parenti C; Gereau RW; Chiechio S
Mol Pain; 2014 Nov; 10():68. PubMed ID: 25406541
[TBL] [Abstract][Full Text] [Related]
24. Erasers of histone acetylation: the histone deacetylase enzymes.
Seto E; Yoshida M
Cold Spring Harb Perspect Biol; 2014 Apr; 6(4):a018713. PubMed ID: 24691964
[TBL] [Abstract][Full Text] [Related]
25. Pain management in pancreatic cancer.
Hameed M; Hameed H; Erdek M
Cancers (Basel); 2010 Dec; 3(1):43-60. PubMed ID: 24212605
[TBL] [Abstract][Full Text] [Related]
26. Mu opioids and their receptors: evolution of a concept.
Pasternak GW; Pan YX
Pharmacol Rev; 2013; 65(4):1257-317. PubMed ID: 24076545
[TBL] [Abstract][Full Text] [Related]
27. HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain.
Denk F; Huang W; Sidders B; Bithell A; Crow M; Grist J; Sharma S; Ziemek D; Rice ASC; Buckley NJ; McMahon SB
Pain; 2013 Sep; 154(9):1668-1679. PubMed ID: 23693161
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?
Koutsounas I; Giaginis C; Theocharis S
World J Gastroenterol; 2013 Feb; 19(8):1173-81. PubMed ID: 23482354
[TBL] [Abstract][Full Text] [Related]
29. Visceral pain: the neurophysiological mechanism.
Sengupta JN
Handb Exp Pharmacol; 2009; (194):31-74. PubMed ID: 19655104
[TBL] [Abstract][Full Text] [Related]
30. Cancer is a preventable disease that requires major lifestyle changes.
Anand P; Kunnumakkara AB; Sundaram C; Harikumar KB; Tharakan ST; Lai OS; Sung B; Aggarwal BB
Pharm Res; 2008 Sep; 25(9):2097-116. PubMed ID: 18626751
[TBL] [Abstract][Full Text] [Related]
31. Current aproach to cancer pain management: Availability and implications of different treatment options.
Nersesyan H; Slavin KV
Ther Clin Risk Manag; 2007 Jun; 3(3):381-400. PubMed ID: 18488078
[TBL] [Abstract][Full Text] [Related]
32. Cytokines, inflammation, and pain.
Zhang JM; An J
Int Anesthesiol Clin; 2007; 45(2):27-37. PubMed ID: 17426506
[TBL] [Abstract][Full Text] [Related]
33. Endogenous opioids inhibit early-stage pancreatic pain in a mouse model of pancreatic cancer.
Sevcik MA; Jonas BM; Lindsay TH; Halvorson KG; Ghilardi JR; Kuskowski MA; Mukherjee P; Maggio JE; Mantyh PW
Gastroenterology; 2006 Sep; 131(3):900-10. PubMed ID: 16952558
[TBL] [Abstract][Full Text] [Related]
34. Contribution of the peripheral 5-HT 2A receptor to mechanical hyperalgesia in a rat model of neuropathic pain.
Nitanda A; Yasunami N; Tokumo K; Fujii H; Hirai T; Nishio H
Neurochem Int; 2005 Nov; 47(6):394-400. PubMed ID: 16051396
[TBL] [Abstract][Full Text] [Related]
35. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.
Celada P; Puig M; Amargós-Bosch M; Adell A; Artigas F
J Psychiatry Neurosci; 2004 Jul; 29(4):252-65. PubMed ID: 15309042
[TBL] [Abstract][Full Text] [Related]
36. [Involvement of peripheral 5-HT2A receptor activation in inflammatory pain].
Nakanishi O; Ishikawa T
Nihon Rinsho; 2001 Sep; 59(9):1675-80. PubMed ID: 11554035
[TBL] [Abstract][Full Text] [Related]
37. Cytokine modulation is necessary for efficacious treatment of experimental neuropathic pain.
Sacerdote P; Franchi S; Moretti S; Castelli M; Procacci P; Magnaghi V; Panerai AE
J Neuroimmune Pharmacol; 2013 Mar; 8(1):202-11. PubMed ID: 23242694
[TBL] [Abstract][Full Text] [Related]
38. Pathogenesis and Treatment of Pancreatic Cancer Related Pain.
Lohse I; Brothers SP
Anticancer Res; 2020 Apr; 40(4):1789-1796. PubMed ID: 32234867
[TBL] [Abstract][Full Text] [Related]
39. 5HT2A modulation attenuates pancreatic cancer induced pain mouse model by inhibiting HDAC.
Fan W; Yang X; Zhou L; Xu J; Huang W; Tripathi AS
Acta Cir Bras; 2024; 39():e392324. PubMed ID: 38629654
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
